AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca uS 401(k) Plan — Notes receivable from participants / participant loans ($) ($)
Form 11-K Statements of Net Assets Available for Benefits
Latest, FY2025
47,578,351
Period ended Dec 31, 2025
Change on a year earlier
+3.4%
46,022,222 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | US 401(k) Plan — Notes receivable from participants / participant loans ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 47,578,351 | +3.4% | Form 11-K FY2025 (AstraZeneca US 401(k) Plan) ↗ |
| FY2024 | Dec 31, 2024 | 46,022,222 | +9.1% | Form 11-K FY2025 (AstraZeneca US 401(k) Plan) ↗ |
| FY2023 | Dec 31, 2023 | 42,200,155 | +19.7% | Form 11-K FY2024 (AstraZeneca US 401(k) Plan) ↗ |
| FY2022 | Dec 31, 2022 | 35,262,521 | -3.8% | Form 11-K FY2023 (AstraZeneca US 401(k) Plan) ↗ |
| FY2021 | Dec 31, 2021 | 36,637,552 | -7.0% | Form 11-K FY2022 (AstraZeneca US 401(k) Plan) ↗ |
| FY2020 | Dec 31, 2020 | 39,384,411 | +2.7% | Form 11-K FY2021 (AstraZeneca US 401(k) Plan) ↗ |
| FY2019 | Dec 31, 2019 | 38,330,513 | – | Form 11-K FY2020 (AstraZeneca US 401(k) Plan) ↗ |
Cite this data
StockData. (2026). AstraZeneca US 401(k) Plan — Notes receivable from participants / participant loans ($) ($), annual FY2019–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/plan11k_participant_loans
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.